Search clinical trials for: Coagulation factor Xa inhibitor

Total 92277 results

VarmX B.V.

Recruiting

Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral Anticoagulant

Coagulation Disorder

Netherlands
Lebanese University
Haykel Hospital

Recruiting

Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms (CAT_PB)

Cardiovascular Diseases | Immune System Diseases | Cancer | Breast Cancer | Hepatocellular Carcinoma | Lung Cancer | Chemotherapy | Solid Tumor | Prostate Cancer | Thromboembolism | Colon Cancer | Immunotherapy | Inflammatory Diseases

Lebanon
Xijing Hospital

Recruiting

Low-dose NOAC Versus GDMT After LAAO (RECORD-III)

Atrial Fibrillation

China
Jilin University

Recruiting

Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction (ACTonLVT)

ST-segment Elevation Myocardial Infarction (STEMI) | Left Ventricular Thrombus

China
Xijing Hospital

Recruiting

LAAO Versus NOAC in Patients With AF and PCI

Atrial Fibrillation | Percutaneous Coronary Intervention

China
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-330 for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation

Coagulation Disorder

United States, Spain, Belgium, France, Netherlands
University of Florida
Medical University of South Carolina; National Institute of Neurological Disorders... and other collaborators

Recruiting

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA)

Stroke | Intracranial Arteriosclerosis

United States
Brian O'Neill MD
Lifetech Scientific (Shenzhen) Co., Ltd.

Not yet recruiting

Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF (CORRAL-AF)

Atrial Fibrillation | Left Atrial Appendage Thrombosis | CVA

United States
Nantes University Hospital

Recruiting

Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels (UniXa)

Atrial Fibrillation | Venous Thromboembolism | Anticoagulation

France
Assiut University

Not yet recruiting

TF, TFPI and Plasmin as Novel Bio-markers in Early Diagnosis of Lupus Nephritis

Lupus Nephritis
Pfizer

Active, not recruiting

Anticoagulation in Patients With Venous Thromboembolism and Cancer (VICTORIE)

Neoplasms | Embolism

United Kingdom
Pfizer

Active, not recruiting

High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France (HELIOS-AF)

Atrial Fibrillation

United Kingdom
Ottawa Hospital Research Institute
Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR)... and other collaborators

Active, not recruiting

Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients (AIRPORT-MPN)

Primary Myelofibrosis | Venous Thromboembolism (VTE) | Polycythemia Vera (PV) | Essential Thrombocythemia (ET) | JAK2 Mutation | Myeloproliferative Neoplasm (MPN)

Canada
VarmX B.V.

Completed

Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects

Coagulation Disorder

Netherlands
Thomas Kander

Completed

The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM

Bleeding | Trauma | Hypothermia | Acidosis

Sweden
University of California, San Francisco
Patient-Centered Outcomes Research Institute; Kaiser Permanente

Completed

Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study (ALTERNATIVE)

Venous Thromboembolism | Anticoagulants and Bleeding Disorders

United States
Doasense GmbH

Active, not recruiting

Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects (PHAPOCU)

Anticoagulant Therapy

Germany
Hadassah Medical Organization

Completed

Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus

Acute Myocardial Infarction | Anticoagulants and Bleeding Disorders | Left Ventricular Thrombosis

Israel
Bayer

Terminated

Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors

Hemophilia A and B

Australia, United Kingdom, Taiwan, Japan, Korea, Republic of, Austria, Bulgaria, Hungary, Italy, France, New Zealand
LifeBridge Health
Janssen Scientific Affairs, LLC

Unknown

Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy

Coronary Artery Disease | Peripheral Artery Disease

United States
Perosphere Pharmaceuticals Inc, a wholly owned...

Completed

Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT

Healthy

United States
Perosphere Pharmaceuticals Inc, a wholly owned...

Completed

Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT

Healthy

United States
Samsung Medical Center

Completed

Safety and Efficacy of Edoxaban in Thoracoscopic Ablation

Atrial Fibrillation | Anticoagulants and Bleeding Disorders

Korea, Republic of
Perosphere Pharmaceuticals Inc, a wholly owned...
Quintiles, Inc.

Completed

Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban

Anticoagulation Reversal

United States
Perosphere Pharmaceuticals Inc, a wholly owned...
Quintiles, Inc.

Completed

Variability of Whole Blood Clotting Time Measurements in Ex Vivo Human Blood Samples Spiked With Anticoagulants

Healthy
Hospital Geral Roberto Santos

Terminated

Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis (RIWA)

Stroke | Valve Heart Disease | Anticoagulants and Bleeding Disorders | Prostheses and Implants

Brazil
University of North Carolina, Chapel Hill
National Heart, Lung, and Blood Institute (NHLBI)

Completed

The Effect of Rivaroxaban in Sickle Cell Disease

Sickle Cell Anemia | Sickle Cell-Beta0-Thalassemia

United States
Janssen Research & Development, LLC
Bayer

Completed

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients (MARINER)

Heart Failure | Rheumatic Diseases | Respiratory Insufficiency | Infectious Diseases | Stroke Acute

United States, Poland, Ukraine, United Kingdom, Germany, Spain, Argentina, Belarus, Colombia, Israel, Mexico, Portugal, Bulgaria, Romania, Serbia, South Africa, Turkey, Canada, Australia, Netherlands, Denmark, Greece, Peru, Brazil, Russian... and more
Second Affiliated Hospital, School of Medicine,...

Unknown

A Prospective Study in Chinese Patients With Lower Extremity Ankle Fracture of Oral Anticoagulants to Prevent Venous Thromboembolism (VTE)

Venous Thromboembolism | Anticoagulants and Bleeding Disorders | Foot Ankle Injuries

China
Bayer

Withdrawn

Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia

Hemophilia
Turku University Hospital
Helsinki University Central Hospital

Completed

NOAC Plasma Concentration and Blood Coagulation in Healthy Volunteers (EdoRot)

Blood Coagulation Disorder

Finland
Hennepin Healthcare Research Institute

Completed

Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease (TACTICAL-HIV)

HIV Infection | Inflammation | Coagulation

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Phase I Study of Direct Coagulation Factor Xa Inhibitor SYHA136 Tablets in Chinese Healthy Volunteers

Venous Thrombosis
Samsung Medical Center

Unknown

Edoxaban for the Treatment of Coagulopathy in Patients With Active Cancer and Acute Ischemic Stroke: a Pilot Study. (ENCHASE Study) (ENCHASE)

Correction of Cancer-related Coagulopathy With Novel Oral Anticoagulant (Edoxaban)

Korea, Republic of
Hopital Lariboisière

Unknown

Evolution of Coagulation Activity in Non Valvular Atrial Fibrillation Patients Under Apixaban (ECAN)

Coagulation Disorder | Non Valvular Atrial Fibrillation

France
Janssen Research & Development, LLC
Bayer

Completed

A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis

End-Stage Renal Disease

United States
Bayer

Completed

Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement (RECORD 2)

Venous Thromboembolism | Prevention

Denmark, Italy, China, Indonesia, Colombia, Portugal, United States, Australia, Korea, Republic of, Taiwan, Canada, Estonia, New Zealand, Brazil, Mexico, South Africa, Peru, United Kingdom, Latvia, India, Lithuania, Sweden, Norway
Green Cross Corporation
Parexel

Completed

A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers

Healthy Volunteers

United States
Bayer

Completed

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement. (RECORD 4)

Venous Thromboembolism

Poland, United States, India, Denmark, Canada, Sweden, Bulgaria, Israel, Lithuania, Norway, Pakistan, Mexico, Sri Lanka
Bayer

Completed

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement. (RECORD 3)

Venous Thromboembolism | Prevention

Belgium, Italy, Poland, Spain, China, France, Denmark, Netherlands, Austria, Germany, Mexico, South Africa, Sweden, Colombia, Israel, Canada, Norway, Peru, Czech Republic
Shanghai Zhongshan Hospital

Completed

The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery

Lung Neoplasms | Esophageal Neoplasms | Venous Thromboembolism

China
Gines Escolar
Ministry of Health, Spain

Unknown

Reversal of the Antithrombotic Action of New Oral Anticoagulants (REVANT)

Hemorrhage | Thrombosis | Anticoagulant-induced Bleeding | Anticoagulant Overdosage

Spain
AstraZeneca

Not yet recruiting

FAITH - Factor XA Inhibitor-Related InTracranial Haemorrhage (FAITH)

InTracranial Haemorrhage
Hospital Sirio-Libanes
Daiichi Sankyo

Not yet recruiting

Vitamin K AntagonISt, Factor Xa Inhibitor Or Nothing In Atrial Fibrillation And DIalytic End-stage Renal DiseasE (VISIONAIRE) (VISIONAIRE)

Chronic Kidney Diseases | Atrium; Fibrillation
Brazilian Clinical Research Institute
Alliança Diagnostic

Not yet recruiting

Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke (ARCHIMEDES)

Ischemic Stroke
International Bio service

Not yet recruiting

Bioequivalence Study of Apixaban 5 mg Film-coated Tablets in Healthy Thai Volunteers

Healthy Volunteer
Insel Gruppe AG, University Hospital Bern

Recruiting

Predicting Outcomes in ICH Patients on Direct Factor Xa Inhibitors (FIRE-Xa)

Intra Cerebral Hemorrhage

Switzerland
Azienda Ospedaliero, Universitaria Ospedali Riuniti

Recruiting

Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population

Intracardiac Thrombus

Italy
Queen Mary University of London

Not yet recruiting

Thromboprophylaxis in Lower Limb Immobilisation (TiLLI)

Thrombosis | Injury Leg
Peking Union Medical College Hospital
Xiangya Hospital of Central South University; Ruijin Hospital; China-Japan Friendship...

Recruiting

The Study of Monitoring and Dosing Guidance of Direct Oral Anticoagulants Based on Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics

Pulmonary Embolism

China

Search clinical trials for: Coagulation factor Xa inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations